La cadena de opciones muestra datos clave de las opciones de acciones de Envoy Medical a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Envoy Medical..

Envoy Medical (NASDAQ:COCH) Bolsa, Cadena de Opciones

Envoy Medical

Envoy Medical Inc is a hearing health company focused on providing innovative medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life.

Envoy Medical, Inc. - Class A Common Stock

Envoy Medical Inc

Cochlear Ltd

WIIM

PROP

Prairie Operating shares are trading lower after the company announced a public offering of $200 million shares.

In an effort to bring South Korea's defense sector into the U.S. investment scene, Exchange Traded Concepts launched the Hanwha Asset Management's PLUS Korea Defense Industry Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KDEF#NYSE">KDEF</a>), offering investors <a href="https://www.benzinga.com/etfs">exposure to South Korea's thriving defense industry</a>.
"We are enthusiastic to introduce the PLUS Korea Defense Industry Index ETF (KDEF) to the U.S. market," said Hanwha CEO Kim Jong-ho. "Expanding on the foundation of our Plus K-Defense ETF listed in Korea, this launch represents an opportunity to provide U.S. investors with exposure to Korea's defense industry. We appreciate the support of Exchange Traded Concepts in bringing this ETF to the NYSE Arca."
KDEF aims to mirror the total return performance of the Korea Defense Industry Index. The fund comes with a net expense ratio of 0.65%, which is competitive.
Also Read: <a href="https://www.benzinga.com/25/02/43542002/calamos-new-cpsf-etf-offers-growth-with-a-safety-net">Calamos&#8217; New CPSF ETF Offers Growth With A Safety Net</a>
The Korea Defense Industry Index focuses on South Korean companies engaged in defense-related operations. This includes firms specializing in shipbuilding, satellite telecommunications, civil engineering and utility system construction, among other sectors. The new ETF aims to take advantage of this exposure.
To be included in the index, companies must have a minimum market capitalization of at least 300 billion Korean Won—approximately $206 million in U.S. dollars as of February 5, 2025. No single constituent holding is allowed to exceed 20% of the index's overall weighting. KDEF follows the index closely, with at least 80% of its investments allocated to securities within the Korea Defense Industry Index. 
Stability and impressive growth rates make South Korea a key market of interest and the safest route to invest in South Korean securities is through ETFs. Other popular ETFs with exposure to South Korean sectors are Franklin FTSE South Korea ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLKR#NYSE">FLKR</a>) and iShares MSCI South Korea ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EWY#NYSE">EWY</a>), both of which have gained about 8% year-to-date.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/real-estate/reit/25/02/43545630/reit-winners-and-losers-januarys-trends-reshaping-2025">REIT Winners And Losers: January&#8217;s Trends Reshaping 2025</a></li>
</ul>
Photo: Shutterstock

New ETFs

ETFs

FLKR

KDEF

South Korea's Defense Sector Gets A US Gateway With KDEF ETF

TNXP

Tonix Pharmaceutical shares are trading higher after the company provided preliminary Q4 financial results.

Editor&#8217;s note: This story has been updated with additional details.
U.S. employment growth lost steam in January, with job growth coming in well below expectations and marking a significant slowdown <a href="https://www.benzinga.com/news/econ-s">from the previous month. </a>
Nonfarm payrolls rose by 143,000 in January 2025, marking a sharp slowdown from the upwardly revised 307,000 in December and missing economist expectations of 170,000, as tracked by TradingEconomics.
The softer-than-expected data hints at a gradual cooling in hiring momentum. The official jobs report also reveals a weaker-than-expected unemployment rate and hotter-than-expected wage growth, indicating mixed signals about the health of the U.S. labor market.
&#8220;In January, job gains occurred in health care, retail trade, and social assistance. Employment declined in the mining, quarrying, and oil and gas extraction industry,&#8221; the Bureau of Labor Statistics stated.
November&#8217;s total nonfarm payroll employment was revised higher by 49,000, increasing from 212,000 to 261,000, while December&#8217;s figure rose by 51,000, from 256,000 to 307,000.
Despite the weaker hiring pace, the unemployment rate surprisingly inched down from 4.1% to 4% in January, beating expectations of a stable reading.
Average hourly earnings, a key measure of wage inflation, spiked 0.5% month-over-month, topping expectations of 0.3% and marking the highest increase since January 2024. On an annual basis, wages increased 4.1%, up from 3.9% previously, and beating estimates of 3.8%. 
Beyond the headline numbers, Friday&#8217;s job market report also included the annual benchmark revision to the establishment survey and updated population controls in the household survey. 
The total nonfarm employment gain for the year ending March 2024 was revised down from 2,900,000 to 2,346,000.
<h3 class="wp-block-heading">Market Reaction</h3>
Financial markets showed little reactions to the jobs report, with U.S. equity futures holding flat as investors reassessed the Fed's policy outlook. 
The U.S. dollar index, tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>), inched up by 0.2%, driven by rising Treasury yields.
The yield on the 10-year Treasury note was up by 5 basis points to 4.49% by 9 a.m. ET Friday. Yields on both longer- and shorter-dated maturities rose in a similar fashion. The iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) was 0.6% lower in premarket trading.
Gold, which is tracked by the SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>), held steady at $2,865 per ounce, hovering at record highs. 
Sector-wise, communication services outperformed, up 0.5%, while consumer discretionary stocks lagged, down 0.6%.
On Thursday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) closed 0.4% higher.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/02/43544975/banks-win-first-regulatory-relief-as-fed-softens-stress-test-rules-scraps-climate-risks-financial-stocks-hit-record-highs">Fed Eases Bank Stress Tests, Drops Climate Risks: Financial Stocks Hit Record Highs</a></li>
</ul>
Photo via Shutterstock.

Broad U.S. Equity ETFs

Currency ETFs

Econ #s

Economics

Markets

iShares Trust Barclays 20+ Year Treasury Bond Fund

PowerShares DB US Dollar Index Bullish Fund

US Economy Adds Fewer Than Expected Jobs In January, Unemployment Rate Slows, Wage Growth Spikes (UPDATED)

PowerShares Exchange Traded Fund Trust Dynamic Mid Cap Value Portfolio

Perella Weinberg shares are trading higher after the company reported better-than-expected Q4 financial results.

As part of this transformation, the Company has conducted a comprehensive, organization-wide analysis to determine the appropriate team size and structure. Following this review, the Company has completed a headcount restructuring process aimed at streamlining operations and reducing costs. This includes a 20% reduction in workforce across the Company to create operational efficiencies and align resources to support our technology-driven objectives. CFO Don Quinby noted, "Workforce reductions are always difficult and never a decision we make lightly. We are making every effort to treat our departing colleagues with respect and gratitude for their contributions and support them in their transition. These measures are expected to strengthen Fr8Tech's financial results over 2025 and better position the Company to reach profitability on an adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) basis by the end of the year."

News

Management

FRGT

Fr8Tech Announces 20% Workforce Reduction To Streamline Operations And Reduce Costs; Aims For Profitability On Adjusted EBITDA Basis By End Of 2025

Wedbush analyst Nick Setyan upgrades Spectrum Brands Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPB#NYSE">SPB</a>) from Neutral to Outperform and raises the price target from $6 to $10.

Upgrades

Price Target

Analyst Ratings

Wedbush Upgrades Spectrum Brands Holdings to Outperform, Raises Price Target to $10

CLFD

Clearfield shares are trading lower after the company reported worse-than-expected Q1 sales results.

Fortive Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTV#NYSE">FTV</a>) shares are trading lower after the company&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43557376/fortive-reports-strong-fourth-quarter-and-full-year-2024-results-introduces-first-quarter-and-full" rel="noreferrer noopener">reported&nbsp;fourth-quarter&nbsp;results</a>.
Revenue grew&nbsp;2% year-over-year (Y/Y) to $1.620 billion,&nbsp;missing the consensus of&nbsp;$1.624 billion.
Core Growth Sales by segments: Intelligent Operating Solutions $710.8 million (+<a href="https://d1io3yog0oux5.cloudfront.net/_b6473ba34b04e3c63d57920de052a56b/fortive/db/924/11185/pdf/FTV-4Q-2024-Earnings-Presentation.pdf" target="_blank" rel="noreferrer noopener">4.1</a>% Y/Y), Precision Technologies $567.7 million (-0.4% Y/Y) and Advanced Healthcare Solutions $341.8 million (+3.2% Y/Y).
The company&#8217;s adjusted operating margin is up 100 basis points Y/Y to 28.7% in the quarter. Adjusted EPS of $1.17, <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">beating the consensus of $1.12</a>. It also reported an operating cash flow of $502 million and a free cash flow of $465 million in the quarter.
&#8220;Continued growth in our Intelligent Operating Solutions (IOS) and Advanced Healthcare Solutions (AHS) segments was driven by steady demand for our safety and productivity solutions and increased contributions from FBS-driven product innovations,&#8221; said James A. Lico, president and CEO.
&#8221;We saw strong order growth across all of our segments, including the second consecutive quarter of double-digit orders growth for our Precision Technologies (PT) segment. This momentum drove sequential improvement in PT core growth and supports our view of a gradual recovery as we move through 2025.&#8221;
Outlook:&nbsp;For FY25, Fortive expects revenue of $6.23&nbsp;billion&nbsp;–&nbsp;$6.35&nbsp;billion&nbsp;versus a consensus of&nbsp;$6.488 billion and adjusted EPS&nbsp;of&nbsp;$4.00&nbsp;–&nbsp;$4.12&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">versus the consensus of&nbsp;$3.85</a>.
For the&nbsp;first quarter&nbsp;of FY25, Fortive anticipates revenue of&nbsp;$1.48 billion –$1.51 billion&nbsp;(consensus:&nbsp;$1.565 billion) and adjusted EPS of&nbsp;$0.83 –&nbsp;$0.86 (consensus&nbsp;$0.91).
Investors can gain exposure to the stock via&nbsp;Themes Natural Monopoly ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CZAR#NASDAQ">CZAR</a>) and Themes Robotics &amp; Automation ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOTT#NASDAQ">BOTT</a>).
Price Action:&nbsp;FTV shares are down 3.57% at $76.99 premarket at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43335937/palo-alto-taiwan-semiconductor-fortive-and-a-major-financial-stock-on-cnbcs-final-trades" target="_blank" rel="noreferrer noopener">Palo Alto, Taiwan Semiconductor, Fortive And A Major Financial Stock On CNBC&#8217;s &#8216;Final Trades&#8217;</a></li>
</ul>
Photo: Shutterstock

Earnings

Equities

Large Cap

Guidance

Movers

BOTT

CZAR

Fortive Q4: EPS Tops, Revenue Misses, CEO Confident In 2025 Recovery

DENN

Denny's shares are trading higher after Wedbush upgraded the stock from Neutral to Outperform and raised its price target from $6 to $10.

Two-year follow-up data from 34 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit, from 12 months to 24 months.
78% of subjects maintained a clinically meaningful benefit of more than 3 points in rVCSS at 24 months, with an average improvement of 8.2 points among the responder cohort.
Subjects continued to experience a median 75% reduction in pain at 24 months.
Interim follow-up data indicate sustained improvements across all venous specific quality-of-life(QoL) indicators.
PMA application for the VenoValve submitted in November 2024, with an FDA decision expected in the second half of 2025.
IRVINE, CA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / February 7, 2025 / enVVeno Medical Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNO#NASDAQ">NVNO</a>) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that interim two-year follow-up data on 34 subjects from the VenoValve U.S. pivotal trial will be presented today by Dr. Matthew Smeds, Professor of Surgery in the Division of Vascular and Endovascular Surgery at Saint Louis University and Principal Investigator for the trial, at the <a href="https://pr.report/6xb2">Vascular and Endovascular Surgery Society (VESS) 2025 Annual Winter Meeting</a>, being held February 6-9, 2025 in Breckenridge, CO. The Company has submitted a pre-market authorization (PMA) application for the VenoValve to the U.S. Food and Drug Administration (FDA), and the review process is ongoing, with a decision anticipated in the second half of 2025.
Key interim two-year follow-up data being presented at VESS includes:
78% of subjects (n=25/32) maintained a clinically meaningful benefit, defined as an improvement of 3 or more points in the revised Venous Clinical Severity Score (rVCSS).
Among the responder cohort, the average rVCSS improvement increased from 6.6 points at 12 months to 8.2 points at 24 months, demonstrating increasing benefit over time.
At 24 months, subjects continued to experience a median 75% reduction in pain, as measured by the Visual Analog Scale (VAS).
Patient-reported outcomes also demonstrated sustained improvements across all venous specific QoL indicators (VEINES-QoL/Sym) from 12 months to 24 months.
Among the subjects with core lab-evaluable data at 24 months, a 100% device patency rate was observed in all 27 subjects.
The rVCSS is a clinically validated scoring system used to track the progression or regression of venous diseases. The FDA previously indicated that an improvement of 3 or more points in rVCSS would be evidence of the VenoValve's clinical benefit.

Biotech

General

NVNO

enVVeno Medical Announces Hancock Jaffe's VenoValve Trial Shows 75% Pain Reduction at 24 Months; 78% Of Patients Maintain Over 3-Point Improvement In rVCSS At 24 Months; FDA Decision Anticipated In H2 2025

Graham shares are trading lower after the company reported worse-than-expected Q3 revenue results.

SRAD

Sportradar shares are trading higher after the company announced a long-term partnership extension with Major League Baseball, which includes MLB acquiring an equity stake in the company.

Pagaya Technologies shares are trading higher after Citigroup upgraded the stock from Neutral to Buy and raised its price target from $13 to $14.5.

<a href="https://www.sec.gov/Archives/edgar/data/1796022/000119312525022317/d919091ds3asr.htm" title="https://www.sec.gov/Archives/edgar/data/1796022/000119312525022317/d919091ds3asr.htm">https://www.sec.gov/Archives/edgar/data/1796022/000119312525022317/d919091ds3asr.htm</a>

Offerings

STEP

StepSpstone Group Files For Mixed Shelf; Size Not Disclosed

Sports

MLB Has Acquired Equity Stake In Sportradar; Under New Terms, Sportradar Will Exclusively Distribute MLB's Ultra-Low Latency Official Data, Media Content And AV Content

LESL

Leslie's shares are trading lower after Telsey Advisory Group cut its price target on the stock from $3.75 to $3.0

AZPN

Elliott Investment Management L.P. Which Manages Funds In Aspen Technolog Issued The Following Statement Regarding The Com's Recently Announced Agreement With Emerson Electric Co. ""As The Largest Minority Investor In Aspentech, We Disagree With The Company's Decision To Support A $265.00 Per Share Tender Offer By Its Majority Stockholder, Emerson, To Acquire The Aspentech Shares It Does Not Already Own...."

Media

MLB And Sportradar Extend Exclusive Partnership Through 2032

McEwen shares are trading lower after the company announced a $95 million convertible senior offering via private placement.

Lake Street analyst Frank Takkinen maintained a Buy rating on Envoy Medical (COCH – Research Report) today and set a price target of $6.00. The com...

Envoy Medical (COCH) Receives a Buy from Lake Street

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Arcutis Biotherapeutics (ARQT – Research Report) and...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Envoy Medical (COCH) announces that its Investigational Device Exemption, IDE, application for its pivotal study of the Acclaim Fully Implanted Coc...

Envoy Medical receives FDA approval to initiate study for hearing device

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Butterfly Network (BFLY – Research Report) and Envoy...

Analysts Offer Insights on Healthcare Companies: Butterfly Network (BFLY) and Envoy Medical (COCH)

Envoy Medical (COCH) announces a peer-reviewed publication in Otology & Neurotology, discussing early experiences with and highlighting potential b...

Envoy Medical announces publication on Acclaim CI

Reports Q3 revenue $56,000 vs. $80,000 last year. "The progress and accomplishments of late have been extremely important to Envoy Medical (COCH) a...

Envoy Medical reports Q3 EPS (37c) vs. 13c last year.

Envoy Medical GAAP EPS of -$0.37 misses by $0.11, revenue of $0.05M misses by $0.02M

Lake Street analyst Frank Takkinen reiterated a Buy rating on Envoy Medical (COCH – Research Report) today and set a price target of $6.00. The com...

Lake Street Sticks to Their Buy Rating for Envoy Medical (COCH)

Envoy Medical (COCH) announces four new patents. The US Patent & Trademark Office issued Envoy Medical Corporation US Pat. No. 12,151,102 on Novemb...

Envoy Medical announces four new patents

In a report released today, Frank Takkinen from Lake Street maintained a Buy rating on Envoy Medical (COCH – Research Report), with a price target ...

Lake Street Keeps Their Buy Rating on Envoy Medical (COCH)

ARQT

BFLY

COCH

Press Releases

Envoy Medical Celebrates First Anniversary Trading as a Public Company under COCH on Nasdaq Capital Market

American Medical Association Approves Groundbreaking New CPT Codes for Totally Implantable Active Middle Ear Hearing Implants Opening New Opportunities for Envoy Medical's Esteem® Device

Comments

Envoy Medical

Envoy Medical (COCH) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL